A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE) (LIFE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01655498 |
|
Recruitment Status :
Completed
First Posted : August 2, 2012
Results First Posted : May 27, 2015
Last Update Posted : May 27, 2015
|
Sponsor:
Pelvalon, Inc.
Information provided by (Responsible Party):
Pelvalon, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this study is to obtain preliminary efficacy and safety data on the use of the LivSure System (now called the "Eclipse™ System") in women with fecal incontinence.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Fecal Incontinence | Device: vaginal bowel control system (LivSure) | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 61 participants |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Clinical Evaluation of the LivSure Vaginal Bowel Control (VBC) System for the Treatment of Fecal Incontinence in Women. |
| Study Start Date : | August 2012 |
| Actual Primary Completion Date : | January 2014 |
| Actual Study Completion Date : | March 2014 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Bowel Movement
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vaginal Bowel Control
A vaginal bowel control system intended to manage fecal incontinence.
|
Device: vaginal bowel control system (LivSure)
Other Names:
|
Primary Outcome Measures :
- Frequency of FI Episodes [ Time Frame: 1 Month ]Subjects with at least a 50% reduction in FI episodes (major or minor soiling)
Secondary Outcome Measures :
- Number of Incontinent Days [ Time Frame: 1 Month ]Change in number of incontinent days while wearing the device during the 2-week assessment period as compared to the baseline 2-week assessment period
- Device-related Adverse Events [ Time Frame: 1month ]The number of overall adverse events rated as probably or definitely related to the study device.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 19 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- History of FI for at least 6 months
- Baseline diary requirement for min # of FI episodes in a two-week period
- Ability to manage investigational device insertion and removal
- Successful fitting of study device
- Willing and able to give written informed consent to participate in the study
Exclusion Criteria:
- Chronic rectal, anal or pelvic pain
- Any vaginal prolapse that extends beyond the plane of the hymen.
- Previous rectal or pelvic floor surgery within the last 12 months (24 months in the case of cancer)
- Congenital anorectal malformation
- Chronic watery diarrhea unmanageable by drugs or diet as primary cause of FI
- Inflammatory bowel disease
- Presence of a vaginal, anal, rectal or urethral fistula or anastomosis
- Presence of a vaginal, rectal or bladder tumor
- Presence of an open wound or tear in the vagina or anus by exam
- Presence or history of rectovaginal fistula
- Atrophic vaginal tissue as determined by symptoms or visualization
- Current vaginal or urinary infection requiring treatment
- History of recurrent urinary or vaginal infections
- Subject is currently pregnant or planning pregnancy in next 5 months
- Concurrent use of any intra-vaginal device that would interfere with LivSure (now called Eclipse) placement or wearing
- Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.) or other factor that the investigator believes would interfere with study participation and/or increase subject risk
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01655498
Locations
| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35249 | |
Sponsors and Collaborators
Pelvalon, Inc.
Investigators
| Principal Investigator: | Holly Richter, PhD, MD | University of Alabama at Birmingham |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Pelvalon, Inc. |
| ClinicalTrials.gov Identifier: | NCT01655498 History of Changes |
| Other Study ID Numbers: |
CA003 |
| First Posted: | August 2, 2012 Key Record Dates |
| Results First Posted: | May 27, 2015 |
| Last Update Posted: | May 27, 2015 |
| Last Verified: | May 2015 |
Keywords provided by Pelvalon, Inc.:
|
fecal incontinence bowel control |
Additional relevant MeSH terms:
|
Fecal Incontinence Rectal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |